Clinical evidence for orphan medicinal products-a cause for concern?

Orphanet Journal of Rare Diseases

Volumn 8, Issue 1, 2013, Pages

  Picavet, Eline ^a   Cassiman, David ^b   Hollak, Carla E ^c   Maertens, Johan A ^b   Simoens, Steven ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Pivotal study; Quality assessment; Quality tool

Indexed keywords

MERCAPTOPURINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CLINICAL DECISION MAKING; CONTROLLED STUDY; DRUG MARKETING; EUROPE; EVIDENCE BASED PRACTICE; HUMAN; QUALITY CONTROL; QUALITY OF LIFE; QUANTITATIVE STUDY;

EVIDENCE-BASED MEDICINE; HUMANS; ORPHAN DRUG PRODUCTION;

EID: 84885450999     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-8-164     Document Type: Article

References (34)

1. Rare diseases and the assessment of intervention: what sorts of clinical trials can we use? Wilcken B, J Inherit Metab Dis 2001 24 291 298 10.1023/A:1010387522195 11405347 (Pubitemid 32479422)
2. Rare diseases, orphan drugs and their regulation: questions and misconceptions. Tambuyzer E, Nat Rev Drug Discov 2010 9 921 929 10.1038/nrd3275 21060315
3. Clinical trials and rare diseases. Gerss JWO, Kopcke W, Rare Dis Epidemiol 2010 686 173 190 10.1007/978-90-481-9485-8-11
4. Systematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson disease. Wiggelinkhuizen M, Tilanus ME, Bollen CW, Houwen RH, Aliment Pharmacol Ther 2009 29 947 958 10.1111/j.1365-2036.2009. 03959.x 19210288
5. Orphan drugs, orphan diseases: the first decade of orphan drug legislation in the EU. Joppi R, Bertele V, Garattini S, Eur J Clin Pharmacol 2013 69 1009 1024 10.1007/s00228-012-1423-2 23090701
6. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. Kesselheim AS, Myers JA, Avorn J, JAMA 2011 305 2320 2326 10.1001/jama.2011.769 21642684
7. Determinants for successful marketing authorisation of orphan medicinal products in the EU. Putzeist M, Heemstra HE, Garcia JL, Mantel-Teeuwisse AK, Gispen-de Wied CC, Hoes AW, Leufkens HG, Drug Discov Today 2012 17 352 358 10.1016/j.drudis.2011.10.027 22094244
8. Access to orphan drugs despite poor quality of clinical evidence. Dupont AG, Van Wilder PB, Br J Clin Pharmacol 2011 71 488 496 10.1111/j.1365-2125.2010. 03877.x 21395641
9. Orphan drugs revisited. McCabe C, Tsuchiya A, Claxton K, Raftery J, QJM 2006 99 341 345 10.1093/qjmed/hcl033 16504983
10. Enzyme replacement therapy for Anderson-Fabry disease. El Dib RP, Nascimento P, Pastores GM, Cochrane Database Syst Rev 2013 2 CD006663
11. Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Rombach SM, Smid BE, Bouwman MG, Linthorst GE, Dijkgraaf MG, Hollak CE, Orphanet J Rare Dis 2013 8 47 10.1186/1750-1172-8-47 23531228
12. Development and validation of COMPASS: clinical evidence of orphan medicinal products-an assessment tool. Picavet E, Cassiman D, Aertgeerts B, Simoens S, Orphanet J Rare Dis 2013
13. European Medicines Agency. http://www.ema.europa.eu/ema/
14. Efficient ways exist to obtain the optimal sample size in clinical trials in rare diseases. van der Lee JH, Wesseling J, Tanck MW, Offringa M, J Clin Epidemiol 2008 61 324 330 10.1016/j.jclinepi.2007.07.008 18313556
15. Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European medicines agency. Regnstrom J, Koenig F, Aronsson B, Reimer T, Svendsen K, Tsigkos S, Flamion B, Eichler HG, Vamvakas S, Eur J Clin Pharmacol 2010 66 39 48 10.1007/s00228-009-0756-y 19936724
16. Clinical trials and rare diseases: a way out of a conundrum. Lilford RJ, Thornton JG, Braunholtz D, BMJ 1995 311 1621 1625 10.1136/bmj.311.7020.1621 8555809 (Pubitemid 26002712)
17. The ongoing evolution of endpoints in oncology. McCain J, Manag Care 2010 19 1 11 21128520
18. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA. Heemstra HE, Leufkens HG, Rodgers RP, Xu K, Voordouw BC, Braun MM, Drug Discov Today 2011 16 73 80 10.1016/j.drudis.2010.11. 006 21094692
19. Evidence-based medicine for rare diseases: implications for data interpretation and clinical trial design. Behera M, Kumar A, Soares HP, Sokol L, Djulbegovic B, Cancer Control 2007 14 160 166 17387301 (Pubitemid 46515152)
20. The problems of clinical trials and registries in rare diseases. Luisetti M, Campo I, Scabini R, Zorzetto M, Kadija Z, Mariani F, Ferrarotti I, Respir Med 2010 104 Suppl 1 42 S44 20413285
21. EUdraCT https://eudract.ema.europa.eu/
22. ClinicalTrials.gov http://clinicaltrials.gov/
23. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ, Control Clin Trials 1996 17 1 12 10.1016/0197-2456(95) 00134-4 8721797 (Pubitemid 26120810)
24. Benefits, challenges and obstacles of adaptive clinical trial designs. Chow SC, Corey R, Orphanet J Rare Dis 2011 6 79 10.1186/1750-1172-6-79 22129361
25. A guide to the design and analysis of small clinical studies. Kianifard F, Islam MZ, Pharm Stat 2011 10 363 368 10.1002/pst.477 21140524
26. Which health-related quality-of-life outcome when planning randomized trials: disease-specific or generic, or both? A common factor model. Ades AE, Lu G, Madan JJ, Value Health 2013 16 185 194 10.1016/j.jval.2012.09.012 23337230
27. Adequacy of health-related quality of life measures in children under 5 years old: systematic review. Grange A, Bekker H, Noyes J, Langley P, J Adv Nurs 2007 59 197 220 10.1111/j.1365-2648.2007.04333.x 17627625
28. Enzyme replacement therapy for Fabry's disease. Waldek S, Germain DP, Wanner C, Warnock DG, Lancet 2010 375 1523 1524 20435225
29. Boersig C, Why NDAs fail-15 pitfalls and how to avoid them http://65.17.196.124/pdf/nda.pdf
30. Evidence-based medicine and rare diseases. Day S, Rare Dis Epidemiol 2010 686 41 53 10.1007/978-90-481-9485-8-3
31. EUnetHTA, Collaboration between EMA and EUnetHTA-development of consensus on HTA methodologies http://www.hta-rus.ru/files/pavlovic-1-eng-1341389991.pdf
32. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Desnick RJ, Fabry Disease Clinical Trial Study Group, Ann Intern Med 2007 146 77 86 10.7326/0003-4819-146-2-200701160-00148 17179052 (Pubitemid 351640010)
33. Adaptive designs in clinical trials. Bowalekar S, Perspect Clin Res 2011 2 23 27 10.4103/2229-3485.76286 21584178
34. Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum. Simoens S, Picavet E, Dooms M, Cassiman D, Morel T, Appl Health Econ Health Policy 2013 11 1 3 10.1007/s40258-012-0004-y 23329382